We are live on ! Find out more
TAK icon

Takeda Pharmaceutical
TAK

358 hedge funds and large institutions have $1.82B invested in Takeda Pharmaceutical in 2026 Q1 according to their latest regulatory filings, with 56 funds opening new positions, 174 increasing their positions, 58 reducing their positions, and 38 closing their positions.

Upgrade to unlock
New
Increased
Maintained
Reduced
Closed

more call options, than puts

Call options by funds: $ | Put options by funds: $

more repeat investments, than reductions

Existing positions increased: | Existing positions reduced:

more first-time investments, than exits

New positions opened: | Existing positions closed:

more capital invested

Capital invested by funds: $ → $

3% more funds holding

Funds holding: 348 → 358 (+10)

0.45% more ownership

Funds ownership: 2.63% → 3.09% (+0.45%)

Holders
358
Holders Change
Holders Change %
% of All Funds
Holding in Top 10
1
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
New
Increased
Reduced
Closed
Calls
$30.6M
Puts
$1.41M
Net Calls
Net Calls Change

Top Buyers

Rank Fund Capital Flow
1
+$113M
2
+$98.6M
3
+$53.7M
4
CWP
Capital Wealth Planning
Florida
+$15.6M
5
Goldman Sachs
Goldman Sachs
New York
+$14.3M

Top Sellers

Rank Fund Capital Flow
1
-$45M
2
-$29.7M
3
-$24.3M
4
Voloridge Investment Management
Voloridge Investment Management
Florida
-$15M
5
Millennium Management
Millennium Management
New York
-$13.9M
Name Holding Trade Value Shares
Change 		Change in
Stake
Capital Research Global Investors
1
Capital Research Global Investors
California
$354M
Fidelity Investments
2
Fidelity Investments
Massachusetts
$132M
Morgan Stanley
3
Morgan Stanley
New York
$120M
Adage Capital Partners
4
Adage Capital Partners
Massachusetts
$119M
Goldman Sachs
5
Goldman Sachs
New York
$104M
BIP
6
Brandes Investment Partners
California
$82.1M
BlackRock
7
BlackRock
New York
$58.8M
Arrowstreet Capital
8
Arrowstreet Capital
Massachusetts
$57.7M
Renaissance Technologies
9
Renaissance Technologies
New York
$55.4M
UBS Group
10
UBS Group
Switzerland
$50.7M
D.E. Shaw & Co
11
D.E. Shaw & Co
New York
$48.2M
VanEck Associates
12
VanEck Associates
New York
$41.9M
First Trust Advisors
13
First Trust Advisors
Illinois
$36.5M
Northern Trust
14
Northern Trust
Illinois
$36.3M
MAP
15
Managed Asset Portfolios
Michigan
$33.3M
Envestnet Asset Management
16
Envestnet Asset Management
Illinois
$26.1M
QCM
17
Quantinno Capital Management
New York
$23.9M
Wells Fargo
18
Wells Fargo
California
$21M
AQR Capital Management
19
AQR Capital Management
Connecticut
$16.6M
CWP
20
Capital Wealth Planning
Florida
$16.4M
CGH
21
Crossmark Global Holdings
Texas
$14.4M
Stifel Financial
22
Stifel Financial
Missouri
$11.6M
Citadel Advisors
23
Citadel Advisors
Florida
$11.6M
Royal Bank of Canada
24
Royal Bank of Canada
Ontario, Canada
$11.4M
Creative Planning
25
Creative Planning
Kansas
$10.1M
1
2 3 4 5

TAK Hedge Fund Activity: Q1 2026 in Review

358 of the 8,126 institutional investors tracked by Wall St. Rank reported a position in Takeda Pharmaceutical (TAK) for Q1 2026, worth a combined $1.82B — up 39% from $1.31B a quarter earlier.

Buyers outnumbered sellers: 56 funds opened new TAK positions and 38 closed out — a net gain of 18 holders — while 174 added to existing stakes and 58 trimmed.

The largest buyer was Adage Capital Partners, opening a new position worth an estimated $113M. The largest seller was Arrowstreet Capital, cutting an estimated $45M.

  • 358 institutional investors held Takeda Pharmaceutical (TAK) as of Q1 2026, up from 348 in Q4 2025.
  • Funds reported $1.82B of Takeda Pharmaceutical stock for Q1 2026, up 39% quarter-over-quarter.
  • 56 funds opened new Takeda Pharmaceutical positions in Q1 2026 and 38 closed out, a net change of +18 holders.
  • The largest Takeda Pharmaceutical buyer in Q1 2026 was Adage Capital Partners, an estimated $113M added.
  • The largest Takeda Pharmaceutical seller in Q1 2026 was Arrowstreet Capital, an estimated $45M sold.

Based on aggregated 13F filings for Q1 2026.